Effect of Levodopa‐carbidopa Intestinal Gel on Non‐motor Symptoms in Patients with Advanced Parkinson's Disease

BACKGROUND: Levodopa‐carbidopa intestinal gel (LCIG; carbidopa‐levodopa enteral suspension in the United States), delivered via percutaneous gastrojejunostomy (PEG‐J) and titrated in the inpatient setting, is an established treatment option for advanced Parkinson's disease (PD) patients with mo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mov Disord Clin Pract
Main Authors: Standaert, David G., Rodriguez, Ramon L., Slevin, John T., Lobatz, Michael, Eaton, Susan, Chatamra, Krai, Facheris, Maurizio F., Hall, Coleen, Sail, Kavita, Jalundhwala, Yash J., Benesh, Janet
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5724683/
https://ncbi.nlm.nih.gov/pubmed/29242809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12526
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados